Citron Research Out Negative on J2 Global (JCOM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Early Valeant/Walgreens Boots Prescription Trends Continuing to Look Positive - Guggenheim (VRX) (WBA)
March 11, 2016 9:37 AM ESTGuggenheim affirms Valeant Pharma (NYSE: VRX) with a Buy rating and $145 price target following recent dermatology prescription performance checks.
Analyst Louise Chen noted the following on Friday:
VRX dermatology Rxs reached ~80% of their levels prior to any disruption from Philidor (October '15) levels up from ~75% last week. TRx's for derm... MoreJ2 Global (JCOM) Comments on Citron Report; Calls 'Factually Incorrect'
March 11, 2016 6:06 AM ESTj2 Global, Inc. (Nasdaq: JCOM). j2 is aware of a report issued yesterday that we believe is both factually incorrect and wrongly... More
UPDATE: Is J2 Global (JCOM) Short a Blast from the Past?
March 10, 2016 2:06 PM EST(Updated - March 10, 2016 3:04 PM EST)
Some traders are suggesting Citron Research was recommending a short on J2 Global (NASDAQ: JCOM) 10 years ago when it was Stocklemon. It is unclear if this is the case. Shares are hitting the lows of the session down 20%... More
